转移性黑素瘤基因疗法在鼠类实验中获得成功

A potent（有效的，强有力的） anti-tumor gene introduced into mice with metastatic（转移性的，变形的） melanoma（黑素瘤，胎记瘤） has resulted in permanent immune reconfiguration and produced a complete remission（缓解，豁免） of their cancer, according to an article to be published in the December 2010 issue of the Journal of Clinical Investigation. The online version is now available. Indiana University School of Medicine researchers used a modified lentivirus（慢病毒） to introduce a potent anti-melanoma T cell receptor gene into the hematopoietic（造血的） stem cells of mice. Hematopoietic stem cells are the bone marrow cells that produce all blood and immune system cells.

The T cell gene, which recognizes a specific protein found on the surface of melanoma, was isolated and cloned from a patient with melanoma. The gene-modified stems cells were then transplanted back into hosts and found to eradicate（根除，灭绝） metastatic melanoma for the lifetime of the mice.

"We found that the transplantation of gene-modified hematopoietic stem cells results in a new host immune system and the complete elimination of tumor," reported Christopher E. Touloukian, M.D., an assistant professor of surgery and immunology at the IU School of Medicine and a member of the Indiana University Melvin and Bren Simon Cancer Center. "To date, cancer immunotherapies have been hampered（阻碍，限制） by limited and diminishing immune responses over time. We believe this type of translational model opens new doors for patients with melanoma and potentially other cancers by taking advantage of the potent regenerative capacity of hematopoietic stem cells and new advances in gene therapy."

This research was funded by a National Institutes of Health grant.

It has paved the way for a new clinical trial in humans funded by the V Foundation for Cancer Research. The pilot phase I trial will involve treatment of 12 patients and focus primarily on the safety and efficacy of the therapy, said Dr. Touloukian, who is the senior author on the JCI paper and the principal investigator for the clinical study. The clinical trial is expected to begin accruing patients by late 2011.

In 2010, more than 68,000 patients will be diagnosed with melanoma and the disease will be associated with approximately 9,000 deaths. The state of Indiana has the 11th highest rate of melanoma incidence of all 50 states. Current treatments for metastatic melanoma, though exciting and innovative, have been highly toxic and largely unsuccessful with the most patients dying within 6 to 12 months after diagnosis.